분변 칼프로텍틴 검사 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Fecal Calprotectin Test Market - Scope of Report

TMR's report on the global Fecal Calprotectin Test market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Fecal Calprotectin Test market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Fecal Calprotectin Test market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Fecal Calprotectin Test market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Fecal Calprotectin Test market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Fecal Calprotectin Test market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Fecal Calprotectin Test market.

The report delves into the competitive landscape of the global Fecal Calprotectin Test market. Key players operating in the global Fecal Calprotectin Test market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Fecal Calprotectin Test market profiled in this report.

Key Questions Answered in Global Fecal Calprotectin Test Market Report:

• What is the sales/revenue generated by Fecal Calprotectin Test across all regions during the forecast period?
• What are the opportunities in the global Fecal Calprotectin Test market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Fecal Calprotectin Test Market - Research Objectives and Research Approach

The comprehensive report on the global Fecal Calprotectin Test market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Fecal Calprotectin Test market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Fecal Calprotectin Test market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Fecal Calprotectin Test Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Patient Type Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Fecal Calprotectin Test Market Analysis and Forecast, 2017-2031
  • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

• 5.1. Technological Advancement
• 5.2. Diseases Epidemiology
• 5.3. Regulatory Scenario
• 5.4. Pricing Analysis
• 5.5. COVID-19 Impact Analysis

6. Global Fecal Calprotectin Test Market Analysis and Forecast, by Patient Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast, by Patient Type, 2017-2031
  • 6.3.1. Adult
  • 6.3.2. Pediatric
• 6.4. Market Attractiveness Analysis, by Patient Type

7. Global Fecal Calprotectin Test Market Analysis and Forecast, by Assay Type

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast, by Assay Type, 2017-2031
  • 7.3.1. ELISA (Enzyme linked Immunosorbent Assay)
  • 7.3.2. Enzyme Fluoroimmunoassay
  • 7.3.3. Quantitative Immune-chromatography
• 7.4. Market Attractiveness Analysis, by Assay Type

8. Global Fecal Calprotectin Test Market Analysis and Forecast, by Indication

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast, by Indication, 2017-2031
  • 8.3.1. Inflammatory Bowel Disease
  • 8.3.2. Colorectal Cancer
  • 8.3.3. Celiac Disease
• 8.4. Market Attractiveness Analysis, by Indication

9. Global Fecal Calprotectin Test Market Analysis and Forecast, by End-user

• 9.1. Introduction & Definition
• 9.2. Key Findings / Developments
• 9.3. Market Value Forecast, by End-user, 2017-2031
  • 9.3.1. Hospitals
  • 9.3.2. Diagnostic Laboratories
  • 9.3.3. Academic & Research Institutes
• 9.4. Market Attractiveness Analysis, by End-user

10. Global Fecal Calprotectin Test Market Analysis and Forecast, by Region

• 10.1. Key Findings
• 10.2. Market Value Forecast, by Region
  • 10.2.1. North America
  • 10.2.2. Europe
  • 10.2.3. Asia Pacific
  • 10.2.4. Latin America
  • 10.2.5. Middle East & Africa
• 10.3. Market Attractiveness Analysis, by Region

11. North America Fecal Calprotectin Test Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Patient Type, 2017-2031
  • 11.2.1. Adult
  • 11.2.2. Pediatric
• 11.3. Market Value Forecast, by Assay Type, 2017-2031
  • 11.3.1. ELISA (Enzyme linked Immunosorbent Assay)
  • 11.3.2. Enzyme Fluoroimmunoassay
  • 11.3.3. Quantitative Immune-chromatography
• 11.4. Market Value Forecast, by Indication, 2017-2031
  • 11.4.1. Inflammatory Bowel Disease
  • 11.4.2. Colorectal Cancer
  • 11.4.3. Celiac Disease
• 11.5. Market Value Forecast, by End-user, 2017-2031
  • 11.5.1. Hospitals
  • 11.5.2. Diagnostic Laboratories
  • 11.5.3. Academic & Research Institutes
• 11.6. Market Value Forecast, by Country, 2017-2031
  • 11.6.1. U.S.
  • 11.6.2. Canada
• 11.7. Market Attractiveness Analysis
  • 11.7.1. By Patient Type
  • 11.7.2. By Assay Type
  • 11.7.3. By Indication
  • 11.7.4. By End-user
  • 11.7.5. By Country

12. Europe Fecal Calprotectin Test Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Patient Type, 2017-2031
  • 12.2.1. Adult
  • 12.2.2. Pediatric
• 12.3. Market Value Forecast, by Assay Type, 2017-2031
  • 12.3.1. ELISA (Enzyme linked Immunosorbent Assay)
  • 12.3.2. Enzyme Fluoroimmunoassay
  • 12.3.3. Quantitative Immune-chromatography
• 12.4. Market Value Forecast, by Indication, 2017-2031
  • 12.4.1. Inflammatory Bowel Disease
  • 12.4.2. Colorectal Cancer
  • 12.4.3. Celiac Disease
• 12.5. Market Value Forecast, by End-user, 2017-2031
  • 12.5.1. Hospitals
  • 12.5.2. Diagnostic Laboratories
  • 12.5.3. Academic & Research Institutes
• 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.6.1. Germany
  • 12.6.2. U.K.
  • 12.6.3. France
  • 12.6.4. Italy
  • 12.6.5. Spain
  • 12.6.6. Rest of Europe
• 12.7. Market Attractiveness Analysis
  • 12.7.1. By Patient Type
  • 12.7.2. By Assay Type
  • 12.7.3. By Indication
  • 12.7.4. By End-user
  • 12.7.5. By Country/Sub-region

13. Asia Pacific Fecal Calprotectin Test Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Patient Type, 2017-2031
  • 13.2.1. Adult
  • 13.2.2. Pediatric
• 13.3. Market Value Forecast, by Assay Type, 2017-2031
  • 13.3.1. ELISA (Enzyme linked Immunosorbent Assay)
  • 13.3.2. Enzyme Fluoroimmunoassay
  • 13.3.3. Quantitative Immune-chromatography
• 13.4. Market Value Forecast, by Indication, 2017-2031
  • 13.4.1. Inflammatory Bowel Disease
  • 13.4.2. Colorectal Cancer
  • 13.4.3. Celiac Disease
• 13.5. Market Value Forecast, by End-user, 2017-2031
  • 13.5.1. Hospitals
  • 13.5.2. Diagnostic Laboratories
  • 13.5.3. Academic & Research Institutes
• 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.6.1. China
  • 13.6.2. Japan
  • 13.6.3. India
  • 13.6.4. Australia & New Zealand
  • 13.6.5. Rest of Asia Pacific
• 13.7. Market Attractiveness Analysis
  • 13.7.1. By Patient Type
  • 13.7.2. By Assay Type
  • 13.7.3. By Indication
  • 13.7.4. By End-user
  • 13.7.5. By Country/Sub-region

14. Latin America Fecal Calprotectin Test Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Patient Type, 2017-2031
  • 14.2.1. Adult
  • 14.2.2. Pediatric
• 14.3. Market Value Forecast, by Assay Type, 2017-2031
  • 14.3.1. ELISA (Enzyme linked Immunosorbent Assay)
  • 14.3.2. Enzyme Fluoroimmunoassay
  • 14.3.3. Quantitative Immune-chromatography
• 14.4. Market Value Forecast, by Indication, 2017-2031
  • 14.4.1. Inflammatory Bowel Disease
  • 14.4.2. Colorectal Cancer
  • 14.4.3. Celiac Disease
• 14.5. Market Value Forecast, by End-user, 2017-2031
  • 14.5.1. Hospitals
  • 14.5.2. Diagnostic Laboratories
  • 14.5.3. Academic & Research Institutes
• 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 14.6.1. Brazil
  • 14.6.2. Mexico
  • 14.6.3. Rest of Latin America
• 14.7. Market Attractiveness Analysis
  • 14.7.1. By Patient Type
  • 14.7.2. By Assay Type
  • 14.7.3. By Indication
  • 14.7.4. By End-user
  • 14.7.5. By Country/Sub-region

15. Middle East & Africa Fecal Calprotectin Test Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast, by Patient Type, 2017-2031
  • 15.2.1. Adult
  • 15.2.2. Pediatric
• 15.3. Market Value Forecast, by Assay Type, 2017-2031
  • 15.3.1. ELISA (Enzyme linked Immunosorbent Assay)
  • 15.3.2. Enzyme Fluoroimmunoassay
  • 15.3.3. Quantitative Immune-chromatography
• 15.4. Market Value Forecast, by Indication, 2017-2031
  • 15.4.1. Inflammatory Bowel Disease
  • 15.4.2. Colorectal Cancer
  • 15.4.3. Celiac Disease
• 15.5. Market Value Forecast, by End-user, 2017-2031
  • 15.5.1. Hospitals
  • 15.5.2. Diagnostic Laboratories
  • 15.5.3. Academic & Research Institutes
• 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 15.6.1. GCC Countries
  • 15.6.2. South Africa
  • 15.6.3. Rest of Middle East & Africa
• 15.7. Market Attractiveness Analysis
  • 15.7.1. By Patient Type
  • 15.7.2. By Assay Type
  • 15.7.3. By Indication
  • 15.7.4. By End-user
  • 15.7.5. By Country/Sub-region

16. Competition Landscape

• 16.1. Market Player - Competitive Matrix (by tier and size of companies)
• 16.2. Market Share Analysis, by Company (2022)
• 16.3. Company Profiles
  • 16.3.1. Abbexa
    • 16.3.1.1. Company Overview
    • 16.3.1.2. Drug Class Portfolio
    • 16.3.1.3. SWOT Analysis
    • 16.3.1.4. Financial Overview
    • 16.3.1.5. Strategic Overview
  • 16.3.2. ALPCO
    • 16.3.2.1. Company Overview
    • 16.3.2.2. Drug Class Portfolio
    • 16.3.2.3. SWOT Analysis
    • 16.3.2.4. Financial Overview
    • 16.3.2.5. Strategic Overview
  • 16.3.3. Alpha Laboratories
    • 16.3.3.1. Company Overview
    • 16.3.3.2. Drug Class Portfolio
    • 16.3.3.3. SWOT Analysis
    • 16.3.3.4. Financial Overview
    • 16.3.3.5. Strategic Overview
  • 16.3.4. Biomerica
    • 16.3.4.1. Company Overview
    • 16.3.4.2. Drug Class Portfolio
    • 16.3.4.3. SWOT Analysis
    • 16.3.4.4. Financial Overview
    • 16.3.4.5. Strategic Overview
  • 16.3.5. BUHLMANN Laboratories AG
    • 16.3.5.1. Company Overview
    • 16.3.5.2. Drug Class Portfolio
    • 16.3.5.3. SWOT Analysis
    • 16.3.5.4. Financial Overview
    • 16.3.5.5. Strategic Overview
  • 16.3.6. DRG Instruments GmbH
    • 16.3.6.1. Company Overview
    • 16.3.6.2. Drug Class Portfolio
    • 16.3.6.3. SWOT Analysis
    • 16.3.6.4. Financial Overview
    • 16.3.6.5. Strategic Overview
  • 16.3.7. EagleBio
    • 16.3.7.1. Company Overview
    • 16.3.7.2. Drug Class Portfolio
    • 16.3.7.3. SWOT Analysis
    • 16.3.7.4. Financial Overview
    • 16.3.7.5. Strategic Overview
  • 16.3.8. Epitope Diagnostics, Inc.
    • 16.3.8.1. Company Overview
    • 16.3.8.2. Drug Class Portfolio
    • 16.3.8.3. SWOT Analysis
    • 16.3.8.4. Financial Overview
    • 16.3.8.5. Strategic Overview
  • 16.3.9. OPERON, S.A.
    • 16.3.9.1. Company Overview
    • 16.3.9.2. Drug Class Portfolio
    • 16.3.9.3. SWOT Analysis
    • 16.3.9.4. Financial Overview
    • 16.3.9.5. Strategic Overview
  • 16.3.10. R-Biopharm AG
    • 16.3.10.1. Company Overview
    • 16.3.10.2. Drug Class Portfolio
    • 16.3.10.3. SWOT Analysis
    • 16.3.10.4. Financial Overview
    • 16.3.10.5. Strategic Overview
  • 16.3.11. Svar Life Science
    • 16.3.11.1. Company Overview
    • 16.3.11.2. Drug Class Portfolio
    • 16.3.11.3. SWOT Analysis
    • 16.3.11.4. Financial Overview
    • 16.3.11.5. Strategic Overview
  • 16.3.12. Thermo Fisher Scientific, Inc.
    • 16.3.12.1. Company Overview
    • 16.3.12.2. Drug Class Portfolio
    • 16.3.12.3. SWOT Analysis
    • 16.3.12.4. Financial Overview
    • 16.3.12.5. Strategic Overview
  • 16.3.13. Werfen
    • 16.3.13.1. Company Overview
    • 16.3.13.2. Drug Class Portfolio
    • 16.3.13.3. SWOT Analysis
    • 16.3.13.4. Financial Overview
    • 16.3.13.5. Strategic Overview
  • 16.3.14. SENTINEL CH. SpA
    • 16.3.14.1. Company Overview
    • 16.3.14.2. Drug Class Portfolio
    • 16.3.14.3. SWOT Analysis
    • 16.3.14.4. Financial Overview
    • 16.3.14.5. Strategic Overview
  • 16.3.15. Diazyme Laboratories, Inc.
    • 16.3.15.1. Company Overview
    • 16.3.15.2. Drug Class Portfolio
    • 16.3.15.3. SWOT Analysis
    • 16.3.15.4. Financial Overview
    • 16.3.15.5. Strategic Overview
  • 16.3.16. DiAgam
    • 16.3.16.1. Company Overview
    • 16.3.16.2. Drug Class Portfolio
    • 16.3.16.3. SWOT Analysis
    • 16.3.16.4. Financial Overview
    • 16.3.16.5. Strategic Overview